Health · Explainer

How myasthenia gravis antibodies block nerve signals to muscles

Myasthenia gravis antibodies disrupt nerve-to-muscle signalling by reducing functional receptors, disturbing their organisation or damaging the postsynaptic membrane. Depending on the antibody type, they can reduce the availability of functional receptors, disturb their arrangement on the muscle membrane or damage the specialised postsynaptic surface. As a result, an electrical command from the nerve does not always produce a sufficiently strong response in the muscle.

The mechanisms differ according to the immune target. This article follows the signal from the motor-nerve terminal to the muscle membrane, then compares the effects associated with AChR, MuSK and related antibodies. It also examines why repeated activity can expose weakness and how evidence about the thymus fits into AChR-positive disease, using clinical guidance and peer-reviewed mechanistic research.

Woman touching her shoulder with a subtle illustration of nerves, muscle fibres and a neuromuscular junction.
Woman with shoulder muscle fatigue and neuromuscular junction illustration Editorial illustration

How does a healthy neuromuscular junction transmit a nerve signal

For a muscle fibre to contract, an electrical message must first reach the end of its motor nerve. Arrival of that signal opens calcium channels in the nerve terminal, allowing calcium to enter and prompting acetylcholine-filled vesicles to release their contents. Acetylcholine then crosses the microscopic gap separating nerve and muscle and reaches nicotinic receptors concentrated on the postsynaptic membrane (Plomp and Webster, 2025).

When acetylcholine activates enough receptors at the end plate, ion movement across the membrane produces a local electrical response. Once this response becomes sufficiently large, voltage-sensitive sodium channels in the nearby muscle membrane open and generate a propagating action potential. The electrical signal then travels through the fibre and initiates contraction. Acetylcholinesterase removes acetylcholine from the synaptic cleft soon afterwards, terminating the message before the next motor-nerve impulse arrives (Lazaridis and Tzartos, 2020).

Under normal conditions, nerve-to-muscle communication has substantial physiological reserve. A single motor-nerve impulse generally releases enough transmitter to create a postsynaptic response well above the minimum required for muscle excitation. The specialised folds of the end plate place acetylcholine receptors and sodium channels where they can support efficient depolarisation. As a result, small variations in transmitter release usually have little visible effect on muscle strength (Plomp and Webster, 2025).

The main steps are:

  • an action potential reaches the motor nerve terminal;
  • calcium entry triggers acetylcholine release;
  • acetylcholine binds receptors on the muscle end plate;
  • receptor opening creates an end-plate potential;
  • the muscle membrane reaches threshold and fires its own action potential;
  • acetylcholinesterase clears acetylcholine so signalling can reset.

The primary failure in myasthenia gravis usually occurs after the nerve has delivered its chemical message. Acetylcholine may still be released, but the muscle membrane has less capacity to convert that message into sufficient depolarisation. The probability that an individual nerve impulse will fail therefore rises. 

This distinguishes myasthenia gravis from conditions that damage the peripheral nerve itself, such as the [nerve involvement studied in leprosy](/health/experimentally-infected-armadillo-leprosy-research-health). MedlinePlus likewise describes the disease as an [antibody-mediated disturbance](/health?sub=vaccines-immunity) of communication at the nerve-muscle junction (MedlinePlus, 2024).

What do acetylcholine receptor antibodies do in myasthenia gravis

Among the recognised autoimmune forms of myasthenia gravis, AChR antibodies are detected most often. Published reviews place their detection at approximately 85% in generalised disease, compared with roughly 50% when symptoms remain ocular (Phillips and Vincent, 2016; Lazaridis and Tzartos, 2020). These are group-level serological figures rather than a measure of how weak an individual patient will become or which muscles will be affected.

AChR autoantibodies can impair the neuromuscular junction through several related processes. Some reduce normal receptor activity when acetylcholine reaches the postsynaptic membrane. Many pathogenic AChR antibodies belong to the IgG1 or IgG3 subclasses and can connect adjacent receptors, encouraging their clustering and removal from the cell surface. The result is a progressive reduction in the number of functional receptors available at the motor end plate (Phillips and Vincent, 2016).

A further mechanism involves complement activation at the postsynaptic membrane. Terminal complement complexes can injure the specialised folds of the motor end plate and alter the membrane structure needed for efficient excitation. This damage decreases available AChRs and disturbs the organisation of voltage-gated sodium channels. Consequently, an unchanged amount of acetylcholine may generate a smaller postsynaptic response, making threshold failure more likely (Gilhus et al., 2019; Phillips and Vincent, 2016).

In myasthenia gravis, the nerve often releases acetylcholine normally; antibodies mainly reduce the muscle end plate's ability to turn each nerve impulse into a reliable contraction.

The different AChR-related effects can amplify one another. A smaller receptor population reduces the electrical response to released acetylcholine, while disruption of the folded end-plate membrane further weakens the conditions needed for muscle excitation. Experimental models also support a causal role for AChR antibodies: antibody transfer and immune responses directed against AChR can reproduce characteristic defects in neuromuscular transmission (Phillips and Vincent, 2016).

Describing AChR autoimmunity simply as receptor "blocking" therefore misses important parts of the mechanism. Functional interference is possible, but accelerated receptor removal and complement-associated injury to the postsynaptic membrane also contribute substantially. Clinical summaries describe the resulting failure of nerve-muscle communication, while mechanistic studies show that several different antibody actions can produce that same physiological endpoint (Gilhus et al., 2019).

How do MuSK and LRP4 antibodies disrupt receptor organisation

AChR is not the only immune target capable of disturbing neuromuscular transmission. In some patients, autoimmunity affects proteins that control how receptors are assembled and retained on the muscle surface. MuSK is one of the central components of this organising system. Signals initiated when nerve-derived agrin engages LRP4 promote MuSK activity and recruit downstream proteins such as DOK7 and rapsyn, helping to keep AChRs concentrated directly across from the motor-nerve ending (Lazaridis and Tzartos, 2020).

MuSK-positive myasthenia gravis represents a relatively small immunological subgroup. A 2020 review estimated its frequency at about 5% of all cases, although prevalence changes according to population and testing strategy (Lazaridis and Tzartos, 2020). The pathogenic antibodies are mainly IgG4. This subclass behaves differently from the IgG1 and IgG3 antibodies characteristic of AChR-positive disease and has little capacity to trigger the classical complement pathway.

Huijbers and colleagues provided direct experimental evidence for this mechanism in 2013. Patient-derived MuSK IgG4 disrupted communication between LRP4 and MuSK and reduced MuSK phosphorylation after agrin stimulation. The effect occurred without complement activation. By weakening this signalling step, the antibodies interfere with the molecular processes that normally preserve dense AChR clusters at the postsynaptic membrane (Huijbers et al., 2013).

Evidence concerning LRP4 autoantibodies is more heterogeneous. They have been detected particularly in patients whose routine tests are negative for both AChR and MuSK antibodies, but reported prevalence differs markedly between laboratories and patient groups. Experimental work suggests that LRP4-directed immunity can disturb the agrin-LRP4-MuSK signalling network and consequently weaken receptor organisation. The clinical importance of these antibodies is therefore less consistently established than that of AChR or MuSK antibodies (Phillips and Vincent, 2016; Lazaridis and Tzartos, 2020).

These findings show that antibody-positive myasthenia gravis cannot be explained by one molecular pathway. AChR autoantibodies primarily alter receptor availability and may damage the postsynaptic membrane through complement, while MuSK-directed antibodies interfere mainly with the signalling processes that maintain receptor positioning. LRP4-related autoimmunity may disturb the same organisational network at another point. Despite these different targets, all can reduce the reliability with which a nerve impulse activates the muscle fibre.

Target

Typical serology and source

Antibody properties

Main effect at the junction

AChR

~85% generalised; ~50% ocular (Phillips and Vincent, 2016)

Mainly IgG1/IgG3

Receptor loss, complement injury and direct functional interference

MuSK

About 5% overall (Lazaridis and Tzartos, 2020)

Predominantly pathogenic IgG4

Blocks LRP4-MuSK signalling and destabilises AChR clusters

LRP4

Smaller, assay-dependent subgroup (Lazaridis and Tzartos, 2020)

Mostly IgG1

Can interfere with agrin-LRP4-MuSK signalling; frequency and significance vary

Why does weakness worsen with repeated activity and improve after rest

Fatigable weakness is the clinical expression of a neuromuscular junction that has lost much of its normal safety margin. In a healthy junction, the end-plate potential produced by each nerve impulse comfortably exceeds the threshold needed to trigger a muscle action potential. In myasthenia gravis, fewer functional receptors, altered receptor clustering or structural damage to the postsynaptic folds make that margin narrower (Plomp and Webster, 2025).

During repeated nerve activity, the amount of acetylcholine released by successive impulses can fall modestly as immediately available transmitter vesicles are used and replenished. A healthy end plate still has enough reserve for every impulse to remain above threshold. At a myasthenic end plate, the first few impulses may succeed, but a small physiological decline in transmitter release can make later end-plate potentials too small to trigger a muscle action potential in some fibres. The muscle's overall force then falls because fewer fibres respond to each nerve impulse (Phillips and Vincent, 2016).

This mechanism is visible in electrophysiology. Repetitive nerve stimulation can produce a decrement in the compound muscle action potential because progressively fewer muscle fibres reach threshold during a train of stimuli. The test does not mean that the nerve is "running out" of acetylcholine in a simple sense. Rather, normal short-term changes in transmitter release are being exposed by an abnormal postsynaptic safety factor that leaves little room for variation (Phillips and Vincent, 2016).

Rest can temporarily improve performance because the presynaptic terminal has time to replenish readily releasable vesicles and because the junction is no longer being challenged by a rapid sequence of impulses. That improvement does not repair the antibody-mediated defect or restore lost receptors; it simply makes transmission more reliable for a period when the next contractions begin. This matches the characteristic [clinical pattern](/health) described by MedlinePlus: weakness often increases with activity and improves after rest (MedlinePlus, 2024).

The pattern also explains why weakness can fluctuate between muscles and across the day. Different neuromuscular junctions have different anatomical and physiological safety margins, and the amount of activity imposed on a muscle varies continuously. Eye muscles are especially prone to showing early weakness, but the precise reason is multifactorial and cannot be reduced to a single receptor count or one universal threshold. The core principle is consistent: myasthenia gravis makes normal synaptic variation clinically visible because the reserve of transmission has been reduced.

What is the connection between the thymus and myasthenia gravis

The thymus is not part of the neuromuscular junction, but it can be part of the immune process that generates AChR-directed autoimmunity. Its normal role is to educate developing T cells, promoting useful immune responses while deleting or restraining cells that strongly recognise the body's own proteins. When this tolerance system is disturbed, autoreactive T cells can help B cells mature into antibody-producing cells directed against self-antigens (Dragin and Le Panse, 2025).

Thymic pathology is seen most clearly in AChR-positive forms of the disease. Early-onset cases frequently show lymphoid follicular hyperplasia on histological examination, whereas thymoma occurs in a much smaller group. NINDS (2024) notes that in many adults with myasthenia gravis the thymus remains large and that some people develop thymomas, tumours of the thymus. These clinical descriptions combine different ages and antibody-defined groups, so they do not describe every subtype.

Mechanistic research suggests that the thymus may contribute by creating conditions in which AChR-reactive immune cells escape normal control. Thymic epithelial cells and other immune cells can expose AChR-related antigens, while abnormal lymphoid organisation can support interactions between autoreactive B and T cells. Dragin and Le Panse (2025) therefore link thymic dysfunction closely with failed immune tolerance in AChR-positive disease, although the initial trigger and the processes that keep the autoimmune response active remain uncertain.

MuSK-positive myasthenia gravis does not show the same consistent thymic pattern as classical AChR-positive disease. Its dominant antibody subclass and wider immune characteristics are different, and the thymic changes commonly described in early-onset AChR-positive cases are not a defining feature. This distinction shows that similar fatigable muscle weakness can develop from autoimmune mechanisms with substantially different biological backgrounds (Gilhus et al., 2019).

The thymus should therefore be viewed as an important contributor in particular immunological forms of myasthenia gravis rather than as a universal cause of the disorder. In major AChR-positive groups, thymic abnormalities are closely connected with impaired immune tolerance and the emergence of pathogenic autoantibody responses. Other antibody-defined forms do not share the same pattern, and even among AChR-positive patients the thymic findings are not identical.

What is established about antibody mechanisms - and what remains uncertain

Evidence from electrophysiology, pathology and experimental models points to a common functional result despite differences in the immune target. Successful nerve-to-muscle transmission requires acetylcholine delivery from the motor nerve and a postsynaptic membrane with enough properly organised receptors to generate sufficient depolarisation. 

In AChR-positive disease, autoantibodies can reduce receptor availability, impair receptor activity and contribute to complement-related end-plate injury. MuSK-positive disease mainly disturbs the signalling network responsible for maintaining receptor organisation. In both situations, the postsynaptic response moves closer to failure threshold, so some nerve impulses no longer activate the muscle fibre successfully (Gilhus et al., 2019; Plomp and Webster, 2025).

The evidence that the antibodies themselves are pathogenic is also strong. Decades of experimental work with AChR antibodies, and more targeted studies with MuSK IgG4, show that patient antibodies can reproduce key elements of transmission failure rather than merely accompanying the disease. The 2013 MuSK study is particularly clear mechanistically because it demonstrated interference with a defined protein-protein interaction and its downstream phosphorylation pathway (Huijbers et al., 2013).

What remains less certain is the full explanation for why autoimmunity begins in a particular person, why one muscle group is affected more than another, and how best to interpret antibodies against less established targets. LRP4, agrin and several other antibodies have been reported, but their frequency, assay dependence and pathogenic importance are less consistent. Some antibodies may be useful biomarkers without being the main cause of weakness, so detection alone should not be equated with a proven pathogenic mechanism (Lazaridis and Tzartos, 2020). The same caution applies to other antibody tests: in [syphilis serology](/health/cardiolipin-standardization-syphilis-serology-health), a reactive result alone also cannot confirm the diagnosis.

There is also no single numerical antibody level that translates directly into a predictable amount of weakness across all patients. Antibody specificity, subclass, complement activity, receptor reserve, thymic biology and differences among individual neuromuscular junctions all influence the phenotype. Reviews therefore classify myasthenia gravis into immunological and clinical subgroups rather than treating a positive antibody test as a complete description of disease behaviour (Gilhus et al., 2019).

The central model, however, is robust. The motor nerve can send an appropriate electrical signal and release acetylcholine, yet the muscle end plate has lost enough receptors, organisation or membrane integrity that the signal sometimes fails to cross the threshold for contraction. Repeated activity exposes that reduced reserve, producing the characteristic fatigable weakness. That is the clearest link between the molecular action of myasthenia gravis antibodies and the symptom a person experiences.

Frequently asked questions

Is myasthenia gravis a problem with the nerve or the muscle?

Autoimmune myasthenia gravis mainly disrupts the junction between the motor nerve and the muscle, especially the postsynaptic muscle membrane. The nerve can still carry an impulse and release acetylcholine, but antibodies reduce receptor function, receptor density or receptor organisation, so the muscle fibre does not respond reliably to every signal.

Do all people with myasthenia gravis have acetylcholine receptor antibodies?

No. Acetylcholine receptor antibodies are the most common, especially in generalised myasthenia gravis, but some people have antibodies against MuSK or LRP4. A further group has no detectable antibodies on standard assays. The antibody subtype matters because different targets disrupt the neuromuscular junction through different molecular mechanisms.

Why can eye muscles be affected early in myasthenia gravis?

Eye movement and eyelid muscles are commonly affected early, but no single mechanism fully explains their particular vulnerability. Their neuromuscular junctions, firing patterns and functional demands differ from many limb muscles. The general principle is that reduced transmission safety margin becomes clinically visible first in muscles that are especially sensitive to small failures of signalling.

What does acetylcholine do at the neuromuscular junction?

Acetylcholine is the chemical messenger released by a motor nerve when an electrical impulse reaches its terminal. It crosses the synaptic cleft and binds nicotinic acetylcholine receptors on the muscle end plate. Opening enough receptors produces an end-plate potential that reaches threshold and triggers a muscle action potential and contraction.

Does the thymus directly block nerve signals in myasthenia gravis?

No. The thymus does not sit at the neuromuscular junction and does not directly interrupt acetylcholine signalling. Its relevance is immunological: in important AChR-positive subgroups, thymic abnormalities are associated with loss of immune tolerance and the development of autoreactive T- and B-cell responses that support pathogenic antibody production.

Sources

  1. National Institute of Neurological Disorders and Stroke. Myasthenia Gravis. 26 April 2024. https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis
  2. National Library of Medicine. MedlinePlus: Myasthenia Gravis. 10 June 2024. https://medlineplus.gov/myastheniagravis.html
  3. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nature Reviews Disease Primers. 2019;5:30. DOI 10.1038/s41572-019-0079-y
  4. Plomp JJ, Webster RG. Structure and function of the neuromuscular junction in health and myasthenia gravis. International Review of Neurobiology. 2025;182:1–19. DOI 10.1016/bs.irn.2025.04.036
  5. Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Research. 2016;5:F1000 Faculty Rev-1513. DOI 10.12688/f1000research.8206.1
  6. Lazaridis K, Tzartos SJ. Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management. Frontiers in Neurology. 2020;11:596981. DOI 10.3389/fneur.2020.596981
  7. Huijbers MG, Zhang W, Klooster R, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proceedings of the National Academy of Sciences of the USA. 2013;110(51):20783–20788. DOI 10.1073/pnas.1313944110
  8. Dragin N, Le Panse R. Thymic physiology and pathophysiology in Myasthenia Gravis. International Review of Neurobiology. 2025;182:67–88. DOI 10.1016/bs.irn.2025.04.023
Tomas Verren

Tomas Verren — author

Tomas Verren has a background in biomedical sciences and population health, with academic training in human biology, epidemiology, study design and the interpretation of health data. After completing his postgraduate training, he moved into research communicat...

This article is for general information and is not medical advice. It was reviewed for accuracy by a qualified clinician; decisions about your health should be made with your own doctor.

Related